$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS)

<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SEATTLE</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 12, 2026</span> /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATOS">ATOS</a>) (&#34;Atossa&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the &#34;Shares&#34;) of its common stock, par value $0.18 per share (&#34;Common Stock&#34;) (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the &#34;Series Warrants&#34;) and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance. The Series A warrants expire on the five and one-half (5.5) year anniversary of the date of issuance. The short-term Series B warrants expire on the two (2) year anniversary of the date of issuance.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1675432/Atossa1_Logo.jpg?id=OA2704546" title="(PRNewsfoto/Atossa Therapeutics Inc)" alt="(PRNewsfoto/Atossa Therapeutics Inc)"></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Rodman &amp; Renshaw LLC acted as the exclusive placement agent for the offering.</p><p xmlns="http://www.w3.org/1999/xhtml">The aggregate gross proceeds to the Company from the offering were approximately $4.5 million before deducting the placement agent&#39;s fees and other estimated offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $12 million. No assurance can be given that any of the Series Warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the Series Warrants. The Company currently intends to use the net proceeds from the offering for clinical development of its product candidates, working capital and general corporate purposes.</p><p xmlns="http://www.w3.org/1999/xhtml">The securities described above were offered and sold by the Company in a registered direct offering pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-279367) that was filed with the Securities and Exchange Commission (the &#34;SEC&#34;), on May 13, 2024, and declared effective by the SEC on May 23, 2024. The securities offered in the registered direct offering were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying base prospectus relating to the registered direct offering were filed with the SEC and are available on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained from Rodman &amp; Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:info@rodm.com" rel="nofollow" xmlns="http://www.w3.org/1999/xhtml">info@rodm.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Atossa Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATOS">ATOS</a>) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company&#39;s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. More information is available at <a xmlns="http://www.w3.org/1999/xhtml" href="https://atossatherapeutics.com" rel="nofollow">https://atossatherapeutics.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains certain &#34;forward-looking statements&#34; within the meaning of the Private Litigation Reform Act of 1995, including but not limited to, the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of proceeds therefrom. Words such as &#34;expect,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;could,&#34; &#34;would,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;design,&#34; &#34;predict,&#34; &#34;future,&#34; or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.</p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements in this press release, including those regarding the expected closing date of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, the potential exercise of the Series Warrants and potential proceeds therefrom, are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: market and other conditions, our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a Duchenne Muscular Dystrophy or McCune-Albright Syndrome indication, or other indications for our lead program, (Z)-endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa&#39;s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.</p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=SF82960&amp;sd=2026-06-12"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds-302799448.html" target="_blank">https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds-302799448.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Atossa Therapeutics Inc</p>

ATOS

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa closes direct offering with warrants; up to $16.5 million potential proceeds

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Atossa Therapeutics closed a registered direct offering of 1,363,637 shares plus Series A and short-term Series B warrants, raising about $4.5 million upfront with up to $12 million more if warrants are exercised. Warrants become exercisable after six months; Series A expires in 5.5 years and Series B expires in 2 years. Proceeds will fund clinical development, working capital, and general corporate purposes.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ATOS closes registered direct offering of 1,363,637 shares and warrants. Upfront gross proceeds about $4.5 million.</li><li>Series A warrants exercisable after six months; expiry 5.5 years. Series B warrants expire in two years.</li><li>Total potential gross proceeds up to $16.5 million. Proceeds to fund clinical development and general corporate purposes.</li><li>Rodman &amp; Renshaw acted as exclusive placement agent.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ATOS - Atossa Therapeutics, Inc. (ATOS)</strong>: Financing to fund clinical development; dilutive effect on equity near term; potential upside from warrant exercise.</li><li><strong>Rodman &amp; Renshaw LLC (N/A)</strong>: Exclusive placement agent for the offering; no immediate public-market impact.</li><li><strong>Securities and Exchange Commission (N/A)</strong>: Offering filed under shelf registration; regulatory backdrop but no direct market move.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article centers on a financing event affecting ATOS&#039;s capital structure and liquidity, with near-term dilution risk but potential long-term cash runway for clinical programs.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>New share issuance dilutes existing holders and may cap near-term upside.</li><li>Warrants exercisable after six months could unlock upside if stock rises.</li><li>Fundraising signals ongoing capital needs; stock may remain choppy until clinical progress.</li><li>Use of proceeds to fund clinical programs could support longer-term valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Closing date: June 12, 2026.</li><li>Shares offered: 1,363,637; Series A and Series B warrants included.</li><li>Upfront gross proceeds: approximately $4.5 million.</li><li>Potential additional gross proceeds: up to $12 million if all warrants are exercised.</li><li>Warrants exercisable after six months; A-warrants expire 5.5 years; B-warrants expire 2 years.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution pressure likely; warrants offer optional upside within 1–2 years.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SEATTLE</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 12, 2026</span> /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATOS">ATOS</a>) (&#34;Atossa&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the &#34;Shares&#34;) of its common stock, par value $0.18 per share (&#34;Common Stock&#34;) (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the &#34;Series Warrants&#34;) and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance. The Series A warrants expire on the five and one-half (5.5) year anniversary of the date of issuance. The short-term Series B warrants expire on the two (2) year anniversary of the date of issuance.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1675432/Atossa1_Logo.jpg?id=OA2704546" title="(PRNewsfoto/Atossa Therapeutics Inc)" alt="(PRNewsfoto/Atossa Therapeutics Inc)"></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Rodman &amp; Renshaw LLC acted as the exclusive placement agent for the offering.</p><p xmlns="http://www.w3.org/1999/xhtml">The aggregate gross proceeds to the Company from the offering were approximately $4.5 million before deducting the placement agent&#39;s fees and other estimated offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $12 million. No assurance can be given that any of the Series Warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the Series Warrants. The Company currently intends to use the net proceeds from the offering for clinical development of its product candidates, working capital and general corporate purposes.</p><p xmlns="http://www.w3.org/1999/xhtml">The securities described above were offered and sold by the Company in a registered direct offering pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-279367) that was filed with the Securities and Exchange Commission (the &#34;SEC&#34;), on May 13, 2024, and declared effective by the SEC on May 23, 2024. The securities offered in the registered direct offering were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying base prospectus relating to the registered direct offering were filed with the SEC and are available on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained from Rodman &amp; Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:info@rodm.com" rel="nofollow" xmlns="http://www.w3.org/1999/xhtml">info@rodm.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Atossa Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATOS">ATOS</a>) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company&#39;s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. More information is available at <a xmlns="http://www.w3.org/1999/xhtml" href="https://atossatherapeutics.com" rel="nofollow">https://atossatherapeutics.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains certain &#34;forward-looking statements&#34; within the meaning of the Private Litigation Reform Act of 1995, including but not limited to, the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of proceeds therefrom. Words such as &#34;expect,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;could,&#34; &#34;would,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;design,&#34; &#34;predict,&#34; &#34;future,&#34; or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.</p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements in this press release, including those regarding the expected closing date of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, the potential exercise of the Series Warrants and potential proceeds therefrom, are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: market and other conditions, our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a Duchenne Muscular Dystrophy or McCune-Albright Syndrome indication, or other indications for our lead program, (Z)-endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa&#39;s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.</p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=SF82960&amp;sd=2026-06-12"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds-302799448.html" target="_blank">https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds-302799448.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Atossa Therapeutics Inc</p>

Atossa Therapeutics closed a registered direct offering of 1,363,637 shares plus Series A and short-term Series B warrants, raising about $4.5 million upfront with up to $12 million more if warrants are exercised. Warrants become exercisable after six months; Series A expires in 5.5 years and Series B expires in 2 years. Proceeds will fund clinical development, working capital, and general corporate purposes.

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News